Delineating Alzheimer's disease progression with MGAT3, a biomarker for improved prognosis and personalized therapy

• Published in: Biomarkers in medicine Vol. 5; no. 5; p. 645
• Main Authors: Fiala, Milan, Porter, Verna
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.10.2011
• Subjects: Alzheimer Disease - diagnosis; Alzheimer Disease - pathology; Alzheimer Disease - therapy; Alzheimer's disease; Amyloid beta-Peptides - metabolism; Biomarkers; Biomarkers - metabolism; Cholecalciferol - therapeutic use; Clinical medicine; Curcumin - analogs & derivatives; Curcumin - therapeutic use; Diarylheptanoids; Disease Progression; Flow cytometry; Humans; Leukocytes, Mononuclear - metabolism; N-Acetylglucosaminyltransferases - genetics; N-Acetylglucosaminyltransferases - metabolism; Phagocytosis; Precision Medicine; Prognosis; Studies
• ISSN: 1752-0363; 1752-0371; 1752-0371
• DOI: 10.2217/bmm.11.64

According to this immune hypothesis, two functional biomarker tests have been developed by: *Exposing freshly isolated PBMCs of AD patients to FAM-Aβ(1 µg/ml overnight) and testing the Aβuptake by flow cytometry; *Challenging PBMCs with Aβ(2 µg/ml overnight) and testing the transcription of MGAT3 (GnT-III) by reverse transcription PCR [5]. The flow cytometric test had a high sensitivity for AD (94%) and less sensitivity for mild cognitive impairment (60%), and a high specificity (100%) in highly cognitively active subjects age-matched to AD patients, but extremely low specificity (25%) in older caregivers. [...] a normal result of this test suggests the absence of AD, whereas an abnormal result may indicate AD or retirement- and age-appropriate cognitive function with unknown prognosis for future dementia.